deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04715932

Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) (Hesperidin)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)

Sponsor: Ingenew Pharmaceuticals Inc.

Conditions Anosmia Confusion Cough Covid19 Fever Headache Irritable Mood Muscle Weakness Nausea Pain Pain, Abdominal Pain, Chest Pain, Joint Pain, Muscle Shortness of Breath Sore Throat Vomiting
Interventions Hesperidin Placebo
Updated 9 times since 2021 Last updated: Apr 6, 2022 Started: Feb 18, 2021 Primary completion: May 25, 2021 Completion: Jun 7, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Anosmia and Confusion, this trial is completed. The trial is conducted by Ingenew Pharmaceuticals Inc. and has accumulated 9 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshotRecruiting~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshotRecruiting~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshotActive Not Recruiting~Sep 2021 – ~May 2022 · 8 months · monthly snapshotCompleted~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2021 — May 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

  1. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  3. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ingenew Pharmaceuticals Inc.
  • Montreal Heart Institute
Data source: Montreal Heart Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations